Results 211 to 220 of about 27,181 (240)
Some of the next articles are maybe not open access.
Infectious Disease Clinics of North America, 2001
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein +2 more
openaire +3 more sources
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein +2 more
openaire +3 more sources
Meningococcal conjugate vaccines
Expert Opinion on Pharmacotherapy, 2004Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
Shanta M, Zimmer, David S, Stephens
openaire +2 more sources
Meningococcal carriage, meningococcal disease and vaccination
Journal of Infection, 1988Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%)
M K, Hassan-King +2 more
openaire +2 more sources
Current Pharmaceutical Design, 2007
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
2003
The evaluation of meningococcal vaccines in humans is a challenging task. Issues of safety, and benefit to the individual patient and to the community may raise difficult ethical problems. The inherent variability of human responses, the rarity of clinical disease, age-dependence in the immune response, and the role of carriers complicates the ...
P, Farrington, E, Miller
openaire +2 more sources
The evaluation of meningococcal vaccines in humans is a challenging task. Issues of safety, and benefit to the individual patient and to the community may raise difficult ethical problems. The inherent variability of human responses, the rarity of clinical disease, age-dependence in the immune response, and the role of carriers complicates the ...
P, Farrington, E, Miller
openaire +2 more sources